(Q37419072)

20 August 2017

1 reference

title

Recent clinical trials and future therapies (English)

1 reference

20 August 2017

3

Heinz Wiendl

1 reference

20 August 2017

1

Sven G Meuth

1 reference

PubMed ID

19300967

20 August 2017

Christoph Kleinschnitz

series ordinal

2

object named as

Christoph Kleinschnitz

1 reference

20 August 2017

1 December 2008

1 reference

20 August 2017

1 reference

20 August 2017

255 Suppl 6

1 reference

20 August 2017

93-96

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-008-6017-7

20 August 2017

0 references

cites work

Whole brain volume changes in patients with progressive MS treated with cladribine.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-008-6017-7

Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-008-6017-7

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-008-6017-7

The effect of cladribine on T(1) 'black hole' changes in progressive MS.

21 January 2018

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

12 December 2020

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

12 December 2020

Cladribine for multiple sclerosis: review and current status

1 reference

12 December 2020

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

1 reference

12 December 2020

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

1 reference

12 December 2020

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

1 reference

12 December 2020

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

12 December 2020

Cladribine (2-chlorodeoxyadenosine)

1 reference

12 December 2020

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

12 December 2020

The B cell--old player, new position on the team

1 reference

12 December 2020

FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors

1 reference

12 December 2020

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

1 reference

12 December 2020

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

12 December 2020

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

12 December 2020

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

12 December 2020

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

12 December 2020

10.1007/S00415-008-6017-7

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19300967